BROOKLYN, NY October 17, 2011 The Peggy Lillis Memorial Foundation will present Sherwood Gorbach, M.D., Chief Scientific Officer and Senior Vice President of Optimer Pharmaceuticals, Inc. and Distinguished Professor (Emeritus) of Public Health and Medicine at Tufts University, with an achievement award to recognize his nearly four decades of visionary research and pursuit of new treatments for Clostridium difficile infection (CDI) a bacterial infection in the lining of the gut that can cause severe diarrhea, inflammation of the colon and in some cases death. Dr. Gorbach's achievement will be recognized at the Foundation's annual benefit, "FIGHT C. diff," on October 22 in Brooklyn, NY. The event brings together a celebration of the life and legacy of Peggy Lillis and Dr. Gorbach's 40 years of pioneering research, with the shared goal of generating increased C. diff awareness and prevention measures.
"It is our great pleasure to recognize Dr. Gorbach for his longstanding commitment to infectious disease research and contributions to the fight against Clostridium difficile infection," said Christian Lillis, Co-founder and Director of the Peggy Lillis Memorial Foundation. "Dr. Gorbach and the Peggy Lillis Memorial Foundation have a shared goal to increase prevention and minimize death and disability resulting from C. diff. We are thrilled to honor Dr. Gorbach for his lifetime commitment to helping patients and look forward to continuing our efforts to raise awareness about this disease."
As a young infectious disease researcher in 1973, Dr. Gorbach's interest was aroused by the first report from New Zealand of several severe cases of diarrhea and bowel inflammation in patients who had become ill following treatment with an antibiotic. Five years later at Tufts University, he and fellow infectious disease researchers identified Clostridium difficile bacteria as the cause of the outbreak, a discovery that
|Contact: Brittany Yurick|
Edelman Public Relations